Click here for parallel session 20

11:15 – 11:45 The microbiome as novel target in cancer therapy –  Michael Scharl (Switzerland)

11:45 – 12:00 Decoding the gut microbiome of immune checkpoint inhibitor-treated cancer patients: a metagenomic and functional analysis – Merel van Gogh (UMC Utrecht)

12:00 – 12:15 A dysbiotic bacterial community that displaces gut commensals is associated with worse immunotherapy response – Miguel Parra Martinez (NKI)

12:15 – 12:30 Meta-analysis reveals a universal gut microbiome signature for colorectal cancer irrespective of onset age and sequencing method – Selin Pekel (LUMC)